Bengaluru, India

Sanjib Das

This inventor holds 1 USPTO granted patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sanjib Das. Retrieved from https://idiyas.com/inventor/sanjib-das-fayhrwo8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sanjib Das - Innovator in cMET Inhibitors

Introduction

Sanjib Das is a prominent inventor based in Bengaluru, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cMET inhibitors. His innovative work has the potential to impact various therapeutic areas.

Latest Patents

Sanjib Das holds 1 patent related to cMET inhibitors. The patent includes compounds of a specific formula designed for use with cMET. It also encompasses pharmaceutical compositions, kits, and articles of manufacture that incorporate these compounds. Additionally, the patent outlines methods and intermediates useful for synthesizing the compounds, as well as methods for utilizing them effectively.

Career Highlights

Sanjib Das is currently employed at Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His role involves research and development, focusing on innovative solutions to address unmet medical needs. His expertise in the field has been instrumental in advancing the company's objectives.

Collaborations

Sanjib has collaborated with notable colleagues, including Lily Kwok and Shaosong Chu. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Sanjib Das is a dedicated inventor whose work on cMET inhibitors showcases his commitment to advancing pharmaceutical science. His contributions are paving the way for new therapeutic options in the medical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…